Breaks Categories: Stock Spotlights

TuesdayOct 29, 2024 1:00 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article. “Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received…

Continue Reading

ThursdayOct 24, 2024 1:12 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced an upcoming meeting with U.S. Food and Drug Administration (“FDA”) leadership. The focus is to discuss Clene’s CNM-Au8® biomarker and related clinical and survival data for ALS. “FDA’s Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (‘DN1’) review team, as well as recognized key opinion leaders in ALS,…

Continue Reading

TuesdayOct 22, 2024 2:55 pm

BioMedNewsBreaks — Astiva Health Stands out in Upward Trend for Quality Medicare Advantage Plans

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities. A recent article discusses the transformation over the past two decades of Medicare Advantage from a niche option into a primary choice for millions of seniors across the U.S. In this evolving market, companies like Astiva Health are stepping up to meet the growing demand for quality Medicare Advantage plans. The company offers a range of options that prioritize member satisfaction and comprehensive care, with its plans designed to cater to the unique needs of seniors, providing access to extensive networks…

Continue Reading

MondayOct 14, 2024 3:40 pm

BioMedNewsBreaks — Astiva Health Providing Standout Option During Medicare Open Enrollment Period

Astiva is a leading provider of personalized and comprehensive healthcare solutions to diverse communities. “Medicare open enrollment for 2024-2025 begins on Oct. 15, 2024, and closes on Dec. 7, 2024, as noted in a recent Medicare Advocates article… Astiva Health provides a standout option during this critical enrollment period, offering a health plan designed to meet the specialized needs of its members,” a recent article reads. “A key feature of Astiva’s plans is its unmatched rebates and grocery benefits. Members are eligible to receive the full Part B premium rebate of $174.70 monthly, helping to alleviate the financial burden of healthcare…

Continue Reading

FridaySep 20, 2024 2:30 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

Continue Reading

WednesdaySep 18, 2024 2:33 pm

BioMedNewsBreaks — Astiva Health Setting New Standard for Healthcare Delivery to Aging Population

Astiva Health is a leading healthcare provider specializing in delivering personalized and comprehensive solutions to diverse communities. The company is launching a comprehensive community outreach initiative to improve wellness and healthcare access for seniors across Southern California. “This initiative represents a significant expansion of Astiva’s commitment to addressing the unique needs of its growing Medicare Advantage Prescription Drug (‘MAPD’) member base. Astiva Health is leveraging its extensive network of local partnerships to bring healthcare services directly into the communities it serves. By collaborating with neighborhood pharmacies, grocery stores and local organizations, Astiva is ensuring that its members can access essential…

Continue Reading

FridayAug 30, 2024 3:07 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal,” reads a recent article. “The report highlights a 5.4% revenue increase in the edible market,…

Continue Reading

FridayAug 30, 2024 2:39 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions,” a recent article reads. “Clene has conducted extensive…

Continue Reading

FridayAug 30, 2024 2:15 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), recently welcomed four seasoned professionals to its executive team. “Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases. The combined expertise of Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen will enhance strategic initiatives, strengthen communications, refine statistical approaches, and ensure the highest standards of quality. The company looks forward to their…

Continue Reading

ThursdayAug 22, 2024 2:31 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101

PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions. PaxMedica will have a crucial Type C meeting with the FDA, pivotal to the progress of PAX-101, its leading drug candidate for autism treatment, within the regulatory framework… This meeting is a significant event…

Continue Reading